Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer

@article{Lee2012PhaseIS,
  title={Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer},
  author={Keun Seok Lee and In Hae Park and Byung-ho Nam and Jungsil Ro},
  journal={Investigational New Drugs},
  year={2012},
  volume={31},
  pages={152-159}
}
To evaluate the efficacy and tolerability of combined treatment with irinotecan (I) and capecitabine (X), we conducted a phase II study of the IX combination in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC). Patients received 80 mg/m2 I on days 1 and 8 and 1,000 mg/m2 X twice daily on days 1–14 of 21-day cycles until disease progression. The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS